<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689078</url>
  </required_header>
  <id_info>
    <org_study_id>08-003-05</org_study_id>
    <nct_id>NCT00689078</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model</brief_title>
  <official_title>Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ORA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to
      prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic
      suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of
      allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID)
      dosing and 1 week of four times daily (QID) dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Structure:

      Prospective, single center, randomized, double-masked, parallel treatment comparison study.
      Subjects will be randomized to one of the following treatment arms to be dosed bilaterally
      twice daily (BID) for the first dosing period and four times daily (QID) for the second
      dosing period:

        1. Prednisolone Acetate 1% ophthalmic suspension

        2. Prednisolone Acetate 0.12% ophthalmic suspension

        3. Loteprednol Etabonate 0.2% ophthalmic suspension

        4. Tears Naturale® II

      Duration:

      Approximately four (4) weeks

      Controls:

      Artificial Tears (Tears Naturale® II)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching at Baseline (Day 0)</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>A baseline CAC was performed on Day 0. Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 6, Day 7, Day 27 and Day 28. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Day 6</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 6. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Day 7</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 7. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Day 27</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 27. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Itching at Day 28</measure>
    <time_frame>3, 5, 7 minutes post-CAC</time_frame>
    <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 28. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Redness at Baseline (Day 0)</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>A baseline CAC was performed on Day 0. Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 6, Day 7, Day 27 and Day 28. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Redness at Day 6</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 6. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Redness at Day 7</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 7. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Redness at Day 27</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 27. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Redness at Day 28</measure>
    <time_frame>7, 15, 20 minutes post-CAC</time_frame>
    <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 28. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Pred acetate 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pred acetate .12%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lot Etab 0.2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1%</intervention_name>
    <description>One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
    <arm_group_label>Pred acetate 1%</arm_group_label>
    <other_name>Pred Forte (Allergan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 0.12%</intervention_name>
    <description>One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
    <arm_group_label>Pred acetate .12%</arm_group_label>
    <other_name>Pred Mild (Allergan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol Etabonate 0.2%</intervention_name>
    <description>One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
    <arm_group_label>Lot Etab 0.2%</arm_group_label>
    <other_name>Alrex (Bausch &amp; Lomb)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tears Naturale</other_name>
    <other_name>Artificial tears</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age &amp; either sex, any race

          -  Willing and able to follow all instructions

          -  Positive history of ocular allergies

          -  Reproducible positive ocular allergic reaction induced by conjunctival allergen
             challenge

        Exclusion Criteria:

          -  Have planned surgery during trial period

          -  Female currently pregnant, planning a pregnancy or lactating

          -  Use of disallowed medications

          -  Have ocular infections, or ocular conditions that could affect study parameters

          -  Have moderate to severe dry eye

          -  Have used an investigational drug or device within 30 days of start of study

          -  Female that is currently pregnant, planning a pregnancy or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail L Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Medical Society, Alpha Omega Honor Society, American board of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Research Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>August 26, 2010</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2018</results_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic conjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from one site in the US.</recruitment_details>
      <pre_assignment_details>Participant flow and baseline characteristics are presented for the 36 subjects that met all inclusion and none of the exclusion criteria and were randomized to receive Pred Forte, Pred Mild, Alrex, or Tears Naturale. 36 subjects were enrolled, 4 discontinued, and 32 subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pred Forte</title>
          <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Pred Mild</title>
          <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Alrex</title>
          <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>Tears Naturale</title>
          <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pred Forte</title>
          <description>1 drop in each eye up to 4 times over 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pred Mild</title>
        </group>
        <group group_id="B3">
          <title>Alrex</title>
        </group>
        <group group_id="B4">
          <title>Tears Naturale</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.11" spread="6.15"/>
                    <measurement group_id="B2" value="44.11" spread="11.53"/>
                    <measurement group_id="B3" value="44.67" spread="18.65"/>
                    <measurement group_id="B4" value="45.78" spread="14.71"/>
                    <measurement group_id="B5" value="43.67" spread="13.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Baseline (Day 0)</title>
        <description>A baseline CAC was performed on Day 0. Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 6, Day 7, Day 27 and Day 28. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Baseline (Day 0)</title>
          <description>A baseline CAC was performed on Day 0. Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 6, Day 7, Day 27 and Day 28. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="0.507"/>
                    <measurement group_id="O2" value="3.08" spread="0.771"/>
                    <measurement group_id="O3" value="2.61" spread="0.953"/>
                    <measurement group_id="O4" value="2.5" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="0.661"/>
                    <measurement group_id="O2" value="3.47" spread="0.475"/>
                    <measurement group_id="O3" value="3.06" spread="0.682"/>
                    <measurement group_id="O4" value="2.75" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.734"/>
                    <measurement group_id="O2" value="3.44" spread="0.447"/>
                    <measurement group_id="O3" value="3.08" spread="0.685"/>
                    <measurement group_id="O4" value="2.83" spread="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Day 6</title>
        <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 6. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Day 6</title>
          <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 6. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.781"/>
                    <measurement group_id="O2" value="2.19" spread="1.108"/>
                    <measurement group_id="O3" value="2.06" spread="0.904"/>
                    <measurement group_id="O4" value="2.33" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.778"/>
                    <measurement group_id="O2" value="2.59" spread="0.954"/>
                    <measurement group_id="O3" value="2.41" spread="0.963"/>
                    <measurement group_id="O4" value="2.53" spread="0.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.968"/>
                    <measurement group_id="O2" value="2.72" spread="0.891"/>
                    <measurement group_id="O3" value="2.31" spread="1.007"/>
                    <measurement group_id="O4" value="2.14" spread="0.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Day 7</title>
        <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 7. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Day 7</title>
          <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 7. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.858"/>
                    <measurement group_id="O2" value="2.28" spread="1.004"/>
                    <measurement group_id="O3" value="2.09" spread="1.069"/>
                    <measurement group_id="O4" value="2.03" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.894"/>
                    <measurement group_id="O2" value="2.69" spread="1.007"/>
                    <measurement group_id="O3" value="2.03" spread="0.85"/>
                    <measurement group_id="O4" value="1.94" spread="1.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.956"/>
                    <measurement group_id="O2" value="2.75" spread="0.896"/>
                    <measurement group_id="O3" value="1.88" spread="0.982"/>
                    <measurement group_id="O4" value="1.72" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Day 27</title>
        <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 27. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Day 27</title>
          <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 27. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="1.119"/>
                    <measurement group_id="O2" value="2.43" spread="1.231"/>
                    <measurement group_id="O3" value="1.75" spread="1.433"/>
                    <measurement group_id="O4" value="2.03" spread="0.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="1.281"/>
                    <measurement group_id="O2" value="2.64" spread="1.189"/>
                    <measurement group_id="O3" value="2.09" spread="1.239"/>
                    <measurement group_id="O4" value="1.84" spread="0.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="1.314"/>
                    <measurement group_id="O2" value="2.64" spread="1.189"/>
                    <measurement group_id="O3" value="2" spread="1.382"/>
                    <measurement group_id="O4" value="1.72" spread="0.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching at Day 28</title>
        <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 28. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
        <time_frame>3, 5, 7 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching at Day 28</title>
          <description>Post-CAC ocular itching from Day 0 will be compared to post-CAC ocular itching, post-instillation, on Day 28. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.111"/>
                    <measurement group_id="O2" value="2.25" spread="1.267"/>
                    <measurement group_id="O3" value="2.03" spread="1.404"/>
                    <measurement group_id="O4" value="1.75" spread="0.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="1.343"/>
                    <measurement group_id="O2" value="2.64" spread="1.24"/>
                    <measurement group_id="O3" value="2" spread="1.482"/>
                    <measurement group_id="O4" value="1.78" spread="0.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.426"/>
                    <measurement group_id="O2" value="2.71" spread="1.228"/>
                    <measurement group_id="O3" value="1.78" spread="1.417"/>
                    <measurement group_id="O4" value="1.56" spread="0.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Redness at Baseline (Day 0)</title>
        <description>A baseline CAC was performed on Day 0. Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 6, Day 7, Day 27 and Day 28. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Redness at Baseline (Day 0)</title>
          <description>A baseline CAC was performed on Day 0. Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 6, Day 7, Day 27 and Day 28. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.651"/>
                    <measurement group_id="O2" value="2.11" spread="0.532"/>
                    <measurement group_id="O3" value="1.86" spread="0.333"/>
                    <measurement group_id="O4" value="2.08" spread="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.573"/>
                    <measurement group_id="O2" value="2.31" spread="0.349"/>
                    <measurement group_id="O3" value="2.11" spread="0.182"/>
                    <measurement group_id="O4" value="2.25" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="0.537"/>
                    <measurement group_id="O2" value="2.28" spread="0.384"/>
                    <measurement group_id="O3" value="2" spread="0.125"/>
                    <measurement group_id="O4" value="2.06" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Redness at Day 6</title>
        <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 6. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Redness at Day 6</title>
          <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 6. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.515"/>
                    <measurement group_id="O2" value="2.22" spread="0.508"/>
                    <measurement group_id="O3" value="1.84" spread="0.823"/>
                    <measurement group_id="O4" value="2.11" spread="0.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.775"/>
                    <measurement group_id="O2" value="2.41" spread="0.626"/>
                    <measurement group_id="O3" value="2.13" spread="0.327"/>
                    <measurement group_id="O4" value="2.28" spread="0.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.866"/>
                    <measurement group_id="O2" value="2.31" spread="0.691"/>
                    <measurement group_id="O3" value="2.03" spread="0.452"/>
                    <measurement group_id="O4" value="2.17" spread="0.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Redness at Day 7</title>
        <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 7. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Redness at Day 7</title>
          <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 7. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="0.451"/>
                    <measurement group_id="O2" value="1.53" spread="0.761"/>
                    <measurement group_id="O3" value="1.59" spread="0.706"/>
                    <measurement group_id="O4" value="1.59" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.791"/>
                    <measurement group_id="O2" value="1.69" spread="0.894"/>
                    <measurement group_id="O3" value="1.59" spread="0.706"/>
                    <measurement group_id="O4" value="1.66" spread="0.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.765"/>
                    <measurement group_id="O2" value="1.78" spread="0.986"/>
                    <measurement group_id="O3" value="1.47" spread="0.737"/>
                    <measurement group_id="O4" value="1.5" spread="0.973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Redness at Day 27</title>
        <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 27. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Redness at Day 27</title>
          <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 27. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.701"/>
                    <measurement group_id="O2" value="2.14" spread="0.349"/>
                    <measurement group_id="O3" value="1.44" spread="0.32"/>
                    <measurement group_id="O4" value="1.56" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.723"/>
                    <measurement group_id="O2" value="2.11" spread="0.476"/>
                    <measurement group_id="O3" value="1.63" spread="0.567"/>
                    <measurement group_id="O4" value="1.72" spread="0.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.814"/>
                    <measurement group_id="O2" value="1.89" spread="0.575"/>
                    <measurement group_id="O3" value="1.53" spread="0.558"/>
                    <measurement group_id="O4" value="1.72" spread="0.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Redness at Day 28</title>
        <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 28. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
        <time_frame>7, 15, 20 minutes post-CAC</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Pred Forte</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pred Mild</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Alrex</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Tears Naturale</title>
            <description>1 drop in each eye up to 4 times daily for up to 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Redness at Day 28</title>
          <description>Post-CAC ocular redness from Day 0 will be compared to post-CAC ocular redness, post-instillation, on Day 28. Ocular redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular redness score over both eyes was analyzed.</description>
          <population>Intent to Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="0.82"/>
                    <measurement group_id="O2" value="1.96" spread="0.393"/>
                    <measurement group_id="O3" value="1.69" spread="0.637"/>
                    <measurement group_id="O4" value="1.81" spread="0.788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.827"/>
                    <measurement group_id="O2" value="2.11" spread="0.378"/>
                    <measurement group_id="O3" value="1.69" spread="0.753"/>
                    <measurement group_id="O4" value="1.94" spread="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-CAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.791"/>
                    <measurement group_id="O2" value="1.86" spread="0.476"/>
                    <measurement group_id="O3" value="1.69" spread="0.717"/>
                    <measurement group_id="O4" value="1.72" spread="0.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed through study completion, approximately one month. All subjects who received study medication were evaluable for the safety analysis.</time_frame>
      <desc>Throughout the visits, staff collected all Adverse Events reported, elicited or observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pred Forte</title>
          <description>1 drop in each eye up to 4 times daily during a 4 week period</description>
        </group>
        <group group_id="E2">
          <title>Pred Mild</title>
          <description>1 drop in each eye up to 4 times daily during a 4 week period</description>
        </group>
        <group group_id="E3">
          <title>Alrex</title>
          <description>1 drop in each eye up to 4 times daily during a 4 week period</description>
        </group>
        <group group_id="E4">
          <title>Tears Naturale</title>
          <description>1 drop in each eye up to 4 times daily during a 4 week period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Stinging upon instillation of dose 1 QD (Morning dose every day)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increase in IOP (5 unit)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Burning upon instillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lower lid swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ocular fatigue sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Taste Perversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Worsening of Rhinitis 1 hour after instillation of Dose 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Worsening of Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Taste perversion upon instillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching secondary to Posion Ivy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Gomes</name_or_title>
      <organization>ORA</organization>
      <phone>9786858900</phone>
      <email>pgomes@oraclinical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

